ARTICLE | Company News

Vectura, Novartis sales and marketing update

January 27, 2014 8:00 AM UTC

Novartis' Sandoz generic pharmaceuticals division launched AirFluSal Forspiro salmeterol/fluticasone in Denmark to treat patients 12 years and older with asthma and chronic obstructive pulmonary disease (COPD). The product is approved in Denmark, Germany, Sweden and Hungary under the EU's decentralized procedure. The companies could not be reached for details on pricing (see BioCentury, Jan. 20). ...